







an Open Access Journal by MDPI

Pharmacogenomics: Challenges and Future

Guest Editors:

Dr. Mariamena Arbitrio

Institute of Biomedical Research and Innovation (IRIB-CNR), Section of Catanzaro, 88100 Catanzaro, Italy

Dr. Maria Teresa Di Martino

Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, 88100 Catanzaro, Italy

Dr. Francesca Scionti

Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), 98164 Messina, Italy

Deadline for manuscript submissions:

closed (5 September 2023)

Message from the Guest Editors

Dear Colleagues,

Over the past years, the growth of pharmacogenomics (PGx) within the medical community has contributed to improving the practice of precision medicine. The genetic make-up influences interindividual variability in drugs response in terms of dosing, drug efficacy/toxicity, hypersensitivity reactions, drug resistance, and clinical outcome. The discovery of PGx biomarkers may lead to tailored prescription, with a major impact on healthcare costs. Until now, FDA recommendations are provided for over 200 drugs in several therapeutic areas, especially for cancer. However, PGx implementation is still limited, and several barriers need to be overcome. For this Special Issue, contributions from both experts and beginners in the PGx field are invited. We welcome reviews and original research articles covering many aspects of PGx, from the discovery of new PGx biomarkers to methodological strategies to increase PGx knowledge and implementation, including validation of PGx biomarkers for clinical translation Moreover, studies on ethical, legal, and economic aspects and on the role of epigenetic and non-genetic factors are also welcome.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Message from the Editor-in-Chief

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider *Genes* for your next genetics paper?

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank: JCR - Q2 (*Genetics & Heredity*) / CiteScore - Q2 (*Genetics*)

Contact Us